1. Mok, Tony S K, Wu, Yi-Long, Kudaba, Iveta, Kush, Debra, Lopes, Gilberto. 2019. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. In Lancet (London, England), 393, 1819-1830. doi:10.1016/S0140-6736(18)32409-7. https://pubmed.ncbi.nlm.nih.gov/30955977/
2. Pérez-Cabello, Jesús A, Silvera-Carrasco, Lucía, Franco, Jaime M, Pozo, David, Roodveldt, Cintia. 2023. MAPK/MAK/MRK overlapping kinase (MOK) controls microglial inflammatory/type-I IFN responses via Brd4 and is involved in ALS. In Proceedings of the National Academy of Sciences of the United States of America, 120, e2302143120. doi:10.1073/pnas.2302143120. https://pubmed.ncbi.nlm.nih.gov/37399380/
3. Mok, Beverly Y, de Moraes, Marcos H, Zeng, Jun, Mougous, Joseph D, Liu, David R. 2020. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. In Nature, 583, 631-637. doi:10.1038/s41586-020-2477-4. https://pubmed.ncbi.nlm.nih.gov/32641830/
智鼠故事 
